- Conditions
- Peanut Allergy, Multi-food Allergy
- Interventions
- Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 112
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anaphylaxis, Hypotension, Bronchospasm, Angioedema
- Interventions
- Epinephrine, Omalizumab (Xolair), Placebos
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Allergic Asthma
- Interventions
- Xolair
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Valrico, Florida • Hinsdale, Illinois + 4 more
- Conditions
- Milk Allergy
- Interventions
- omalizumab
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- Stanford, California • Boston, Massachusetts
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
- Conditions
- Bullous Pemphigoid
- Interventions
- Rituximab combined with Omalizumab
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Food Hypersensitivity, Anaphylaxis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Milk Allergy
- Interventions
- Placebo for omalizumab, Omalizumab, Milk powder
- Biological · Drug
- Lead sponsor
- Hugh A Sampson, MD
- Other
- Eligibility
- 7 Years to 35 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Stanford, California • Baltimore, Maryland • New York, New York
- Conditions
- Food Allergy
- Interventions
- Omalizumab, Food Flour Buildup
- Drug
- Lead sponsor
- Kari Christine Nadeau
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Interventions
- Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Cypress, California • Glendale, California • Denver, Colorado + 4 more
- Conditions
- Urticaria
- Interventions
- Vitamin D (4,000 IU/day), Vitamin D (400 IU/day), Omalizumab
- Dietary Supplement · Drug
- Lead sponsor
- Selina Gierer, D.O.
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Persistent Allergic Asthma
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 50
- States / cities
- Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
- Conditions
- Asthma
- Interventions
- omalizumab, Rhinovirus (strain 16)
- Drug · Biological
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Asthma
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Allergic Asthma
- Interventions
- Placebo, Omalizumab, Immunotherapy
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Asthma
- Interventions
- omalizumab, omalizumab placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 20 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Immune System Diseases
- Interventions
- Food proteins, Omalizumab
- Dietary Supplement · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Asthma
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 16,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Atopic Dermatitis
- Interventions
- omalizumab
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Moderate-to-severe Allergic Asthma
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Rolling Hills Estates, California • Denver, Colorado • Pembroke Pines, Florida + 9 more
- Conditions
- Asthma
- Interventions
- Xolair®
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Cat Allergy
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Asthma
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Asthma
- Interventions
- Dupilumab, Omalizumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more